Although the results of these prior meta-analyses demonstrated that the frequency of RASSF1 promoter methylation was significantly associated with increased risk of thyroid cancer, our study showed that the influence of RASSF1 promoter methylation was lower than those of CDH1 and SLC5A8 promoter methylation. The gene discussed is CDH1; the disease is thyroid cancer.